845744-10-7

Upstream product

• 67593-29-7 methyl 4-(2-chlorophenyl)-5-cyano-1,4-dihydro-2,6-dimethylpyridine-3-carboxylate 
• 320581-09-7 (2-amino-1,1-dimethyl-ethyl)-carbamic acid tert-butyl ester 
• 845744-09-4 methyl 2-(bromomethyl)-4-(2-chlorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate 

Downstream Products

• 845744-11-8 methyl 2-{[(2-amino-3-methylpropyl)amino]methyl}-4-(2-chlorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate 
• 845743-68-2 methyl 2-{[(2-{[(2S)-3-(2-cyanophenoxy)-2-hydroxypropyl]amino}-2-methylpropyl)amino]methyl}-4-(2-chlorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE

The present invention provides compounds possessing inhibitory activity against β-adrenergic receptors and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for regulating calcium homeostasis, for treating a disease, disorder or condition in which disregulation of calcium homeostasis is implicated, and for treating hypertension, cardiovascular disease, congestive heart failure, myocardial ischemia, cardiomyopathies, stroke or epilepsy.